Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Completed · Phase 3 · NCT02947347
Conditions: Follicular Lymphoma
At a glance
- Research payments reported, 2025
- $482,058
- U.S. investigators named
- 23
- Sites paid
- 18
- Planned or actual enrollment
- 445
About the trial
- Sponsor
- Pharmacyclics LLC. (with Janssen Research & Development, LLC)
- Tested
- Ibrutinib Oral Capsule (drug), Placebo (drug), Rituximab (drug)
- Dates
- Started 2017-01-23; completion 2025-06-09
- Results posted
- Yes
This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study to evaluate the efficacy and safety of ibrutinib in combination with rituximab versus placebo in combination with rituximab in treatment naïve participants with follicular lymphoma (FL).
From ClinicalTrials.gov, last updated 2026-03-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $482,058 in research payments for this study in 2025 (140 payments).
Products named: Imbruvica
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Michael W. Meshad, MD Medical Oncology · Mobile, AL
- Eric M. Bank, M.D. Hematology & Oncology · Solvang, CA
- Sven De Vos, MD Hematology & Oncology · Los Angeles, CA
- Daniel R. Greenwald, M.D. Medical Oncology · Santa Barbara, CA
- Matthew G. Mei, M.D. Hematology · Duarte, CA
- Jamal G. Misleh, MD Hematology & Oncology · Newark, DE
- Ketan D. Doshi, M.D. Medical Oncology · Ocala, FL
- Faithlore P. Gardner, MD Medical Oncology · Cape Coral, FL
- David D. Wright, MD Medical Oncology · Tampa, FL
- Parameswaren Venugopal, M.D. Hematology · Chicago, IL
- Don A. Stevens, M.D. Medical Oncology · Louisville, KY
- Scott A. Anderson, D.O. Hematology & Oncology · Columbia, MO
- Suman Kambhampati, MD Hematology & Oncology · Kansas City, MO
- Apurva Pandey, M.D Medical Oncology · Portland, OR
- Bertrand M. Anz III, M.D. Hematology & Oncology · Chattanooga, TN
- Ian W. Flinn, M.D. Hematology & Oncology · Nashville, TN
- Dai Chihara, MD, PHD Medical Oncology · Houston, TX
- Kristi J. Mcintyre, MD Medical Oncology · Dallas, TX
- Habte A. Yimer IV, M.D. Hematology & Oncology · Tyler, TX
- Jerome H. Goldschmidt JR., M.D. Hematology & Oncology · Christiansburg, VA
- Arvind Chaudhry, MD Hematology & Oncology · Spokane, WA
- Michaela L. Tsai, MD Hematology & Oncology · Seattle, WA
- Lauren W. Veltri, MD Hematology & Oncology · Morgantown, WV
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $107,585
- Ocala Oncology Center Pl $69,695
- Rush University Medical Center, IL $68,778
- US Oncology Research LLC $40,572
- Resnick Neuropsychiatric Hospital at UCLA, CA $38,626
- City of Hope National Medical Ctr $30,770
- Norton Healthcare Inc $25,119
- Swedish Medical Center, WA $24,518
- Sarah Cannon Research Institute $14,779
- Ohsu Hospital and Clinics, OR $11,117
- Medical Oncology Associates Ps $10,534
- Christiana Hospital, DE $10,130
- Wvu Research Corporation $9,937
- Santa Barbara Hematology Oncology M $6,109
- Texas Oncology PA $5,315
- Oncology & Hematology Associates Of $4,357
- Coastal Pharmacy-Orals $2,126
- Capital Region Medical Center $1,992
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.